February 24, 2021
February 24, 2021 – The U.S. FDA has approved an expanded indication for Humira® (adalimumab), manufactured by AbbVie. Humira is now indicated to treat moderately to severely
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
February 23, 2021
February 23, 2021 - An automatic refill sounds great on the surface. Members can make sure they don’t run out of
medication by authorizing their pharmacy to fill their prescription(s) at regular intervals.
February 22, 2021
February 22, 2021 – AstraZeneca, the manufacturer of Imfinzi (durvalumab), has voluntarily withdrawn the drug’s indication to treat locally advanced or metastatic bladder cancer in adults.
February 22, 2021
February 22, 2021 – The U.S. FDA has approved a new indication for Libtayo® (cemiplimab-rwlc), manufactured by Regeneron Pharmaceuticals. The drug is now indicated for first-line
February 17, 2021
February 17, 2021 – The U.S. FDA has partially rescinded approvals for Pfizer’s BeneFIX® (coagulation factor IX, recombinant) and Medexus Pharma’s Ixinity® (coagulation factor IX, recombinant).
February 16, 2021
February 16, 2021 - A new-to-market drug is precisely what it sounds like – a drug that has recently been approved and
released for sale in the United States market.
January 22, 2021
January 22, 2021 –The U.S. FDA has approved LupkynisTM (voclosporin), manufactured by Aurinia
Pharmaceuticals, for use in combination with a background immunosuppressive therapy
January 21, 2021
January 21, 2021 – The U.S. FDA has approved Cabenuva® (cabotegravir/rilpivirine), an extended-release,
injectable, complete regimen for the treatment of HIV-1 infection in adults.